Rho, Italy

Gianluigi Forloni



 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2014-2018

Loading Chart...
Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Gianluigi Forloni

Introduction

Gianluigi Forloni is a prominent inventor based in Rho, Italy. He has made significant contributions to the field of neurodegenerative disease treatment through his innovative research and patented inventions. With a total of two patents to his name, Forloni's work focuses on developing effective therapies for conditions such as Alzheimer's disease.

Latest Patents

Forloni's latest patents involve the creation of novel liposomes that are active in-vivo for treating neurodegenerative diseases. These liposomes comprise phosphatidic acid and/or cardiolipin, along with apolipoprotein E (ApoE) or its derivatives. The modified liposomes, when administered systemically, demonstrate a dramatic in-vivo reduction of amyloid plaques in the central nervous system. This breakthrough allows for effective treatment options for neurodegenerative diseases, particularly Alzheimer's disease.

Career Highlights

Gianluigi Forloni is affiliated with the Università Degli Studi Di Milano-Bicocca, where he conducts his research and development work. His career is marked by a commitment to advancing medical science and improving patient outcomes through innovative solutions.

Collaborations

Forloni collaborates with esteemed colleagues in his field, including Massimo Masserini and Francesca Re. These partnerships enhance the research efforts and contribute to the development of effective treatments for neurodegenerative diseases.

Conclusion

Gianluigi Forloni's contributions to the field of neurodegenerative disease treatment through his innovative patents highlight his dedication to medical research. His work continues to pave the way for advancements in therapies that can significantly impact the lives of those affected by such conditions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…